BOLT
NASDAQ
US
Bolt Biotherapeutics, Inc. - Common Stock
$4.29
▼ $-0.22
(-4.88%)
Vol 16K
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$10.5M
ROE
-97.6%
Margin
-514.8%
D/E
0.00
Beta
0.94
52W
$4–$13
Wall Street Consensus
10 analysts · Apr 20262
Strong Buy
5
Buy
3
Hold
0
Sell
0
Strong Sell
70.0%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 100.0%
Next Report
May 11, 2026
EPS Estimate: $-2.91
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-2.91 | — | — |
| Dec 2025 | $-6.23 | $-3.84 | +$2.39 |
| Sep 2025 | $-5.90 | $-3.72 | +$2.18 |
| Jun 2025 | $-6.58 | $-4.46 | +$2.12 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | — | $1.2M | $1.8M | $2.2M | $2.5M |
| Net Income | — | -$15.9M | -$11.0M | -$8.6M | -$7.1M | -$6.6M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -94.4% | -96.8% | -94.4% | -94.4% | -97.6% | -97.6% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -474.6% | -1303.2% | -834.6% | -834.6% | -514.8% | -514.8% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 3.11 | 3.13 | 3.11 | 3.11 | 3.57 | 3.57 |
Key Ratios
ROA (TTM)
-52.4%
P/S (TTM)
2.02
P/B
0.4
EPS (TTM)
$-22.27
CF/Share
$-1.84
Rev Growth 3Y
+82.8%
52W High
$12.60
52W Low
$4.41
$4.41
52-Week Range
$12.60
Financial Health
Free Cash Flow
-$7.2M
Net Debt
$11.3M
Cash
$11.7M
Total Debt
$23.0M
As of Dec 31, 2025
How does BOLT compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
BOLT valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
2.0
▼
84%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
0.4
▼
85%
below
peers
(2.5)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
BOLT profitability vs Biotechnology peers
ROE
-97.6%
▼
45%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-514.8%
▼
80%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-52.4%
▼
12%
below
peers
(-46.7%)
vs Peers
vs Industry
In line
BOLT financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
3.6
▼
20%
below
peers
(4.4)
vs Peers
vs Industry
Below avg
Beta
0.9
▼
4%
below
peers
(1.0)
vs Peers
vs Industry
Less volatile
BOLT fundamentals radar
BOLT
Peer median
Industry
BOLT profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
BOLT vs peers: key metrics
Top Holders
Top 5: 21.76%Sofinnova Investments, Inc.
7.17%
$603K
Pivotal bioVenture Partners…
4.92%
$414K
Vivo Capital, LLC
3.77%
$317K
Nan Fung Group Holdings Lim…
3.04%
$256K
Renaissance Technologies, L…
2.86%
$241K
As of Dec 31, 2025